- Hologic, Inc. is a global leader in women's health, specializing in innovative medical products and equipment, particularly in diagnostics and surgical solutions.
- In April 2026, Hologic was acquired by funds managed by Blackstone and TPG for up to $79 per share, with José Almeida appointed as CEO to drive future growth and innovation.
- The company recently received FDA approval for its Aptima® HPV Assay, enhancing its cervical health portfolio and demonstrating its commitment to advancing women's health diagnostics.
- Hologic's ideal buyers include healthcare providers and hospitals focused on women's health, as they address critical needs in cervical cancer screening and diagnostics, making them a key player in improving patient outcomes.
Hologic's workforce is organized across 19 departments, with Operations leading at 940 employees, followed closely by Information Technology with 641 and Sales at 637. This distribution indicates a strong emphasis on operational efficiency and technological support, essential for the medical products and equipment industry. The presence of significant headcounts in Community and Social Services (235) and Health Services (226) highlights the company's commitment to integrating healthcare solutions within its operational framework.
Hologic operates across 394 locations, with the largest concentrations in San Diego, CA (615 employees), Marlborough, MA (540), and Bedford, MA (441). The substantial headcount in 'Other' locations, totaling 2,886, suggests a distributed workforce model that enhances operational flexibility. This geographic distribution indicates a strategic presence in key markets while maintaining a significant operational base in Massachusetts, reflecting the company's roots and regional focus.
